Links to 4 New Hepatitis C Articles

[Guest guest]

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

News-Medical.net

By Professor Sandeep Mukherjee, MBBCh, MPH, FRCPC Hepatitis C virus

(HCV)-associated liver disease continues to be the most common indication for

liver transplantation (LT) in the United States accounting for nearly 50% of all

liver transplants. ...

See all stories on this topic »

Pharmasset Adds 3 More Regimens To Hepatitis C Study; Shares Up

Wall Street Journal

Pharmasset Inc. (VRUS) expanded its Electron study of PSI-7977 for the treatment

of chronic hepatitis C to explore three more regimens. Shares were trading 12%

higher at $121.06 premarket. The stock has more than doubled so far this year,

....

See all stories on this topic »

What's Next for Hepatitis C

PLoS Blogs (blog)

By Wapner Without question, the recent approvals of telaprevir (Vertex)

and boceprevir (Merck) for the treatment of hepatitis C infection marks the

beginning of a new time for hepatitis C. This advance is genuinely significant,

and after all ...

See all stories on this topic »Livercancerstudyon tap

San Express

Those other factors include hepatitis C, a leading cause of liver cancer in this

country. Seven percent of the residents in the earlier study were infected with

the virus. Other causes of liver cancer include diabetes, alcohol use and

chemical ...

See all stories on this topic »

[Guest guest]

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

News-Medical.net

By Professor Sandeep Mukherjee, MBBCh, MPH, FRCPC Hepatitis C virus

(HCV)-associated liver disease continues to be the most common indication for

liver transplantation (LT) in the United States accounting for nearly 50% of all

liver transplants. ...

See all stories on this topic »

Pharmasset Adds 3 More Regimens To Hepatitis C Study; Shares Up

Wall Street Journal

Pharmasset Inc. (VRUS) expanded its Electron study of PSI-7977 for the treatment

of chronic hepatitis C to explore three more regimens. Shares were trading 12%

higher at $121.06 premarket. The stock has more than doubled so far this year,

....

See all stories on this topic »

What's Next for Hepatitis C

PLoS Blogs (blog)

By Wapner Without question, the recent approvals of telaprevir (Vertex)

and boceprevir (Merck) for the treatment of hepatitis C infection marks the

beginning of a new time for hepatitis C. This advance is genuinely significant,

and after all ...

See all stories on this topic »Livercancerstudyon tap

San Express

Those other factors include hepatitis C, a leading cause of liver cancer in this

country. Seven percent of the residents in the earlier study were infected with

the virus. Other causes of liver cancer include diabetes, alcohol use and

chemical ...

See all stories on this topic »

[Guest guest]

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

News-Medical.net

By Professor Sandeep Mukherjee, MBBCh, MPH, FRCPC Hepatitis C virus

(HCV)-associated liver disease continues to be the most common indication for

liver transplantation (LT) in the United States accounting for nearly 50% of all

liver transplants. ...

See all stories on this topic »

Pharmasset Adds 3 More Regimens To Hepatitis C Study; Shares Up

Wall Street Journal

Pharmasset Inc. (VRUS) expanded its Electron study of PSI-7977 for the treatment

of chronic hepatitis C to explore three more regimens. Shares were trading 12%

higher at $121.06 premarket. The stock has more than doubled so far this year,

....

See all stories on this topic »

What's Next for Hepatitis C

PLoS Blogs (blog)

By Wapner Without question, the recent approvals of telaprevir (Vertex)

and boceprevir (Merck) for the treatment of hepatitis C infection marks the

beginning of a new time for hepatitis C. This advance is genuinely significant,

and after all ...

See all stories on this topic »Livercancerstudyon tap

San Express

Those other factors include hepatitis C, a leading cause of liver cancer in this

country. Seven percent of the residents in the earlier study were infected with

the virus. Other causes of liver cancer include diabetes, alcohol use and

chemical ...

See all stories on this topic »

[Guest guest]

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

News-Medical.net

By Professor Sandeep Mukherjee, MBBCh, MPH, FRCPC Hepatitis C virus

(HCV)-associated liver disease continues to be the most common indication for

liver transplantation (LT) in the United States accounting for nearly 50% of all

liver transplants. ...

See all stories on this topic »

Pharmasset Adds 3 More Regimens To Hepatitis C Study; Shares Up

Wall Street Journal

Pharmasset Inc. (VRUS) expanded its Electron study of PSI-7977 for the treatment

of chronic hepatitis C to explore three more regimens. Shares were trading 12%

higher at $121.06 premarket. The stock has more than doubled so far this year,

....

See all stories on this topic »

What's Next for Hepatitis C

PLoS Blogs (blog)

By Wapner Without question, the recent approvals of telaprevir (Vertex)

and boceprevir (Merck) for the treatment of hepatitis C infection marks the

beginning of a new time for hepatitis C. This advance is genuinely significant,

and after all ...

See all stories on this topic »Livercancerstudyon tap

San Express

Those other factors include hepatitis C, a leading cause of liver cancer in this

country. Seven percent of the residents in the earlier study were infected with

the virus. Other causes of liver cancer include diabetes, alcohol use and

chemical ...

See all stories on this topic »